2009- Senior Researcher/Group Leader, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet.
In February 2009 I was recruited to Karolinska Institutet to start up a preclinical stroke research group. I am responsible for planning, coordinating and executing work in the area of experimental stroke in diabetes.
July 2013- present, Project Coordinator in degree projects in medicine (Läkarprogrammet I medicin, 30hp). Department of Medical Epidemiology and Biostatistics, Karolinska Institutet.
October 2013- present, Project Manager, Södersjukhuset, Internal medicine. The work aims at increasing collaborations and supervise PhD students within the unit and at developing translational projects within the cardiovascular diseases research area.
2013 Docent in neuroscience, Karolinska Institutet
2011 Course in "Assessment in Higher Education", Karolinska Institutet
2011 Basic Course in Education for University Teachers, Karolinska Institutet
2010 Introductory Doctoral Supervision Course, Karolinska Institutet
2010 Work environment issues and manager responsibilities , Karolinska Institutet
2009 Laboratory Animal Science (FELASA) certificate, Karolinska Institutet
2008 Applied Project Management Courses, Wenell Management AB, Stockholm
2007 Courses in Clinical Trials, Trial Form Support AB, Lund
1998 PhD in Neurobiology, University of Milan, Italy.
1992 University of Milan, Italy, Laurea and M.Sc. Biological Sciences
Stroke, Neurodegeneration and Diabetes
The focus is along two major research lines:
- The identification of efficacious preclinical therapies for the treatment of stroke.
- The study of the cellular mechanisms at the basis of the neurological complications of diabetes.
Stroke affects several million people worldwide, of which a substantial proportion of cases present in patients suffering from diabetes. Diabetes is widespread and represents the fourth leading cause of death in the U.S. About 90 % of the medical and social costs associated with diabetes are dominated by care for macrovascular complications such as stroke.
Alzheimer's disease, dementia and cognitive dysfunction are also ove-represnted in diabetes. However, the underlying mechanisms at the basis of this are still largely unknown.
Recent data published by our research group indicate that the activation of the glucagone-like receptor 1 (GLP-1R) is neuroprotective against stroke in normal and type 2 diabetic rodents.
We have also shown that a rat model of type 2 diabetes presents neuronal loss and neuroinflammation along aging. These results have the potential to help understanding how and when diabetes leads to neurodegeneration.
We also showed that diabetic glucolipotoxicity negatively impacts adult neural stem cells and that neuropeptides Galanin and PACAP can counteract diabetes-induced cell death.
Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells
Journal of gastroenterology 2013;48(3):322-32
GLP-1 secretion by microglial cells and decreased CNS expression in obesity
Journal of neuroinflammation 2012;9():276-
Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats
CLINICAL SCIENCE 2012;122(9-10):473-83
Pituitary Adenylate Cyclase-Activating Polypeptide Counteracts the Impaired Adult Neural Stem Cell Viability Induced by Palmitate
JOURNAL OF NEUROSCIENCE RESEARCH 2012;90(4):759-68
Restorative Effects of Platelet Derived Growth Factor-BB in Rodent Models of Parkinson's Disease
JOURNAL OF PARKINSONS DISEASE 2011;1(1):49-63
The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test
EUROPEAN JOURNAL OF PHARMACOLOGY 2011;650(1):249-55
Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease
JOURNAL OF NEUROSCIENCE RESEARCH 2008;86(2):326-38
Rapid quantification of neurons and stem/progenitor cells in the adult mouse brain by flow cytometry
LETTERS IN DRUG DESIGN & DISCOVERY 2007;4(8):532-539
PACAP promotes neural stem cell proliferation in adult mouse brain
JOURNAL OF NEUROSCIENCE RESEARCH 2004;76(2):205-15
Regulation of postnatal lung development and homeostasis by estrogen receptor beta
MOLECULAR AND CELLULAR BIOLOGY 2003;23(23):8542-52
Estradiol induces differential neuronal phenotypes by activating estrogen receptor alpha or beta
Oestrogen prevention of neural cell death correlates with decreased expression of mRNA for the pro-apoptotic protein Nip-2
JOURNAL OF NEUROENDOCRINOLOGY 2000;12(11):1051-9
Estrogen receptor-dependent regulation of sensory neuron survival in developing dorsal root ganglion
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1999;96(19):10905-10
Pituitary adenylate cyclase activating polypepetide is expressed by developing rat Purkinje cells and decreases the number of cerebellar gamma-amino butyric acid positive neurons in culture
NEUROSCIENCE LETTERS 1999;265(3):207-10
Divergent pathways regulate ligand-independent activation of ER alpha in SK-N-BE neuroblastoma and COS-1 renal carcinoma cells
MOLECULAR ENDOCRINOLOGY 1998;12(6):835-41
Dopaminergic phenotype induced by oestrogens in a human neuroblastoma cell line
EUROPEAN JOURNAL OF NEUROSCIENCE 1997;9(5):1008-16
Dopaminergic phenotype induced by oestrogens in a human neuroblastoma cell line (vol 9, pg 1008, 1997)
EUROPEAN JOURNAL OF NEUROSCIENCE 1997;9(7):1552-1552
Oligonucleotide squelching reveals the mechanism of estrogen receptor autologous down-regulation
MOLECULAR ENDOCRINOLOGY 1997;11(7):938-49
SK-ER3 neuroblastoma cells as a model for the study of estrogen influence on neural cells
BRAIN RESEARCH BULLETIN 1997;44(4):519-23
Cross-coupling between insulin and estrogen receptor in human neuroblastoma cells
MOLECULAR ENDOCRINOLOGY 1996;10(5):499-507
SPECIFICITY OF ACTION OF A HERPES-VIRUS VP16 TETRACYCLINE-DEPENDENT TRANSACTIVATOR IN MAMMALIAN-CELL CULTURES
DNA AND CELL BIOLOGY 1995;14(8):665-71